{"id":"NCT03778931","sponsor":"Stemline Therapeutics, Inc.","briefTitle":"Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer","officialTitle":"Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-10","primaryCompletion":"2021-08-24","completion":"2024-08-22","firstPosted":"2018-12-19","resultsPosted":"2023-12-05","lastUpdate":"2024-10-30"},"enrollment":478,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Elacestrant","otherNames":["RAD1901"]},{"type":"DRUG","name":"Standard of Care","otherNames":["Faslodex, Arimidex, Femara, Aromasin"]}],"arms":[{"label":"Elacestrant","type":"EXPERIMENTAL"},{"label":"Standard of Care (SoC)","type":"ACTIVE_COMPARATOR"}],"summary":"This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) .","primaryOutcome":{"measure":"Progression-free Survival in ESR1-mut Subjects","timeFrame":"From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)","effectByArm":[{"arm":"Elacestrant","deltaMin":3.78,"sd":null},{"arm":"Standard of Care (SoC)","deltaMin":1.87,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":244,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Denmark","France","Greece","Hungary","Ireland","Israel","Italy","Portugal","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["38381994","35584336","31426673"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":237},"commonTop":["Nausea","Fatigue","Arthralgia","Vomiting","Aspartate aminotransferase increased"]}}